MP51-08 PRELIMINARY EXPERIENCE WITH COMPREHENSIVE GENOMIC PROFILING OF GENITOURINARY TUMORS; A TOOL TO DIRECT CLINICAL DECISIONS?

You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Practice Patterns, Quality of Life & Shared Decision Making II1 Apr 2018MP51-08 PRELIMINARY EXPERIENCE WITH COMPREHENSIVE GENOMIC PROFILING OF GENITOURINARY TUMORS; A TOOL TO DIRECT CLINICAL DECISIONS? James Ryan Mark, Victor Kucherov, Robert B Den, Adam P Dicker, Veda Giri, James Luke Godwin, Jean Hoffman-Censits, Costas Lallas, Mark Mann, Peter McCue, Edouard Trabulsi, Karen Knudsen, William K Kelly, and Leonard Gomella James Ryan MarkJames Ryan Mark More articles by this author , Victor KucherovVictor Kucherov More articles by this author , Robert B DenRobert B Den More articles by this author , Adam P DickerAdam P Dicker More articles by this author , Veda GiriVeda Giri More articles by this author , James Luke GodwinJames Luke Godwin More articles by this author , Jean Hoffman-CensitsJean Hoffman-Censits More articles by this author , Costas LallasCostas Lallas More articles by this author , Mark MannMark Mann More articles by this author , Peter McCuePeter McCue More articles by this author , Edouard TrabulsiEdouard Trabulsi More articles by this author , Karen KnudsenKaren Knudsen More articles by this author , William K KellyWilliam K Kelly More articles by this author , and Leonard GomellaLeonard Gomella More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1639AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The rapid expansion of next generation sequencing (NGS) and novel therapeutic agents have allowed the clinical application of targeted therapies in many areas including urologic oncology. FoundationOne (Foundation Medicine, Cambridge MA) is a validated comprehensive genomic profile (CGP) for solid tumors designed to provide clinically actionable information to guide treatment decisions based on a tumor′s genomic profile. Our institution is a member of the Precision Medicine Exchange Consortium (a collaboration between 8 academic cancers to facilitate data exchange, advance research, and support education and applications of precision medicine in oncology and molecular pathology with Foundation Medicine. We reviewed our initial experience with CGP in a series of patients with genitourinary malignancies, most of whom had failed standard therapies. METHODS A retrospective review of our patients with genitourinary cancers sent to Foundation Medicine for CGP between 2/1/2013 and 10/31/2017. RESULTS A total of 150 samples were evaluated by CGP (table 1). At least one gene alteration was identified in 145 (97.0%) of the cases with a total of 185 unique mutations among the cohort. Each patient had a mean of 4.8 (SD 3.0) mutations (range 1-16). For all patients, a total of 45 (31.0%) mutations were identified with FDA approved agents for that disease. 88 (61.0%) patients had mutations with an available therapy FDA approved for another disease. There was at least one clinical trial available to 124 (86.0%) patients. 21 patients (14.0%) had an identifiable genetic alteration and no clinical trial available. Table 1 shows the breakdown of mutations for typical histologies of prostate, urothelial, and clear cell kidney cancer. CONCLUSIONS Tumor genomic profiling using platforms such FoundationOne can yield useful information about specific mutations and druggable targets for patients progressing on standard therapies. This information can lead to informed decision making for determining treatment sequence and also encourage clinical trial participation. We also identified a substantial number of genetic alterations that are not associated with currently available therapeutic agents providing direction for further investigation and drug development. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e687 Advertisement Copyright & Permissions© 2018MetricsAuthor Information James Ryan Mark More articles by this author Victor Kucherov More articles by this author Robert B Den More articles by this author Adam P Dicker More articles by this author Veda Giri More articles by this author James Luke Godwin More articles by this author Jean Hoffman-Censits More articles by this author Costas Lallas More articles by this author Mark Mann More articles by this author Peter McCue More articles by this author Edouard Trabulsi More articles by this author Karen Knudsen More articles by this author William K Kelly More articles by this author Leonard Gomella More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...